Translating Pre-Clinical Research to Clinical Patient Care™

JMSACL

Editorial Structure

Associate Editors : JMSACL

	Anne Bendt, PhD Singapore Lipidomics Incubator (SLING), National University of Singapore, Singapore Lipidomics Anne K Bendt studied Biology focusing on marine biotechnology (Greifswald University, Germany), followed by a PhD in Biochemistry (Cologne University, Germany) employing proteomics and transcriptomics. Driven by her fascination for infectious diseases, she joined the National University of Singapore (NUS) in 2004 to develop lipidomics tools for tuberculosis studies. She is now a Principal Investigator at the Life Sciences Institute, NUS, focussing on translation of mass spec technologies into clinical applications, and serving as the Associate Director of the Singapore Lipidomics Incubator (SLING) taking care of operations and commercialization.

	Melissa Budelier, PhD TriCore Reference Laboratories Toxicology TDM Clinical Implementation Method Development & Validation Proteomics Small Molecules Biomarkers Diagnostics Dr. Budelier the Medical Director of Clinical Chemistry and Toxicology at TriCore Reference Laboratories and Clinical Assistant Professor of Pathology at the University of New Mexico. Her research interests are broadly focused on developing clinically useful, mass spectrometry-based assays to improve diagnosis and treatment of human disease. Her expertise are in Toxicology/TDM, assay development and validation, and protein quantification.

	Christopher Chouinard, PhD Clemson University, Melbourne, Florida, United States Instrumentation Steroids Ion Mobility I received my PhD from University of Florida in 2016, where I developed ion mobility-mass spectrometry (IM-MS) methods for steroids and vitamin D metabolites. I then worked as post-doctoral research at Pacific Northwest National Laboratory, building Structures for Loss Ion Manipulations (SLIM) ion mobility instrumentation for application in metabolomics and proteomics. Since 2018, I have been an Assistant Professor at Florida Institute of Technology. Work in my research group focuses on structurally selective reactions for improved characterization of steroids and other controlled substances with IM-MS.

	Robert Gurke, PhD Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany Lipidomics Metabolomics Biomarkers Clinical Implementation Method Development & Validation Robert Gurke received his diploma in chemistry at the Humboldt-University zu Berlin, Germany in 2012 followed by his doctoral thesis at the Technische Universität Dresden in 2016. After a short period as study director in a GLP-compliant bioanalytical company in Berlin he started working as research associate at the Institute of Clinical Pharmacology in Frankfurt under the guidance of Prof. Geisslinger. Mr Gurke is performing LC-MS/MS analysis since starting his doctoral thesis and gained broad experience in the field of developing and validating methods for the determination of exogenous and endogenous small molecules in different complex matrices.

	Liam Heaney, PhD Loughborough University, Loughborough, United Kingdom Small Molecules Toxicology Quantitative MS Biomarkers Metabolomics Breath Analysis Anti-Doping Dr Liam Heaney is a Senior Lecturer in Bioanalytical Science based in the School of Sport, Exercise and Health Sciences at Loughborough University, UK. His research interests focus principally on the use of high-throughput measurement of small molecule biomarkers, with aligned interests in discovery-based omics applications. These activities include projects that span across multiple disciplines including clinical diagnostic and prognostic applications, nutrition and physiology, and sports anti-doping/drugs of abuse. His work is centered around the application of analytical chemistry applying both gas chromatography and liquid chromatography-mass spectrometry. He sits as an Executive Committee Member of the British Mass Spectrometry Society and was recently voted onto The Analytical Scientists Top 40 Under 40 for his work in promoting the use of mass spectrometry in sport & exercise science/nutrition.

	Daniel Holmes, MD, FRCPC St. Paul’s Hospital, Vancouver, British Columbia, Canada Endocrinology Data Science Small Molecules Automation Sample Prep Daniel Holmes did his undergraduate training in Chemistry and Physics at the University of Toronto before deciding to pursue medicine as a career. He attended medical school at the University of British Columbia where pathology became his area of major interest. The strong influence of his academic mentors led him to enter the Medical Biochemistry residency training program at UBC. This allowed him to use his background knowledge of chemistry in application to medicine. Areas of clinical interest are diagnostic lipidology/endocrinology and research interests are in the utilization of mathematics and computer diagnostics to laboratory medicine.

	Randall Julian, PhD Indigo BioAutomation, Carmel, Indiana, United States Data Science Machine Learning Randy Julian is the Founder and CEO of Indigo BioAutomation. Randy earned a Ph.D. in Chemistry from Purdue University. Dr. Julian worked for 14 years at Eli Lilly using mass spectrometry in natural product drug discovery, high throughput screening for RNA anti-viral compounds, and proteomics and metabolomics in animal models. Randy founded Indigo as a spin-out of Lilly. Indigo develops software that uses machine learning techniques to analyze data from laboratories across the US automatically. Dr. Julian is also is an Adjunct Professor of Chemistry at Purdue.

	Mark Kushnir, PhD ARUP Institute for Clinical & Experimental Pathology, Salt Lake City, Utah, United States Endocrinology Proteomics Small Molecules Biomarkers Method Development & Validation Sample Prep Quantitative MS Clinical Implementation Mark Kushnir is Scientific Director, Mass Spectrometry R&D at ARUP Institute for Clinical and Experimental Pathology and Adjunct Assistant Professor at the Department of Pathology, University of Utah School of Medicine. He received PhD in Analytical Chemistry from Uppsala University (Uppsala, Sweden); his main areas of interest include development, application and clinical evaluation of novel mass spectrometry based clinical diagnostic methods for small molecule, protein and peptide biomarkers. He is author/coauthor of over 100 scientific peer reviewed publications.

	Ruben Y. Luo, PhD, DABCC Stanford University Glycomics Instrumentation Metabolomics New Technologies Proteomics Protein Variant Detection Sample Prep Separations Ruben Y. Luo, PhD, DABCC, FADLM is an Assistant Professor of Pathology at Stanford University and Associate Director of Clinical Chemistry Laboratory at Stanford Health Care. He has been dedicated to innovations in translational laboratory medicine: discovery of novel diagnostic markers and innovation of diagnostic technologies. His research focuses on (1) discovering the clinical diagnostic value of molecular characteristics of protein biomarkers, and (2) developing high-resolution mass spectrometry and label-free optical sensing technologies for characterization and accurate measurement of biomarkers. He completed his clinical chemistry fellowship at University of California San Francisco. Prior to the fellowship, he had several years of work experience in the clinical diagnostic industry. He received his PhD in analytical chemistry from Stanford University, and BS in chemistry from Peking University.

	Laura Smy, PhD, DABCC, MLS (CSMLS) Medical College of Wisconsin Toxicology TDM Quantitative MS Clinical Implementation Method Development & Validation Laura Smy, PhD, DABCC, MLS (CSMLS) is an Associate Professor at the Medical College of Wisconsin. Her clinical duties include Co-director of chemistry and toxicology for the Wisconsin Diagnostic Laboratories and the CLIA director for four Froedtert Community Hospitals. She earned her PhD in Pharmaceutical Sciences and Biomedical Toxicology from the University of Toronto. She completed a Fellowship in Clinical Chemistry at the University of Utah and ARUP Laboratories in Salt Lake City, Utah, honing her expertise in the laboratory medicine and experience with mass spectrometry and toxicologic analysis of alternative sample types.

	Grace van der Gugten, B.Sc. Chemistry Alberta Precision Laboratories Small Molecules Clinical Implementation Grace discovered her love for clinical mass spectrometry when she began working at St Paul's Hospital in Vancouver in the special chemistry mass spec group with Dr. Dan Holmes in late 2010. Grace was challenged in this role but gained a wealth of knowledge and experience over her 10+ years in the SPH laboratory. She puts this experience and knowledge into use in her current role as Lab Scientist in the Newborn Screening and Biochemical Genetics lab at Alberta Precision Laboratories in Edmonton. Grace loves developing streamlined, easy to use (if possible!) clinical mass spectrometry assays; teaching others and helping others succeed; and troubleshooting (especially when the problem is solved!).

	Elizabeth Want, PhD Imperial College London, London, United Kingdom Metabolomics Toxicology Liz is the Waters Senior Lecturer in Molecular Spectroscopy in the Department of Surgery and Cancer. She joined Imperial College in 2006 after working as a postdoctoral researcher at the Scripps Research Institute in La Jolla, CA. At Imperial College, she was initially a postdoctoral researcher for the Consortium for Metabonomic Toxicology (COMET) group. Her research focuses primarily on the development and application of novel MS-based techniques for metabolic phenotyping and on the fusion of MS methods with chemometric analysis, which is currently a significant bottleneck in the analysis pipeline. Broadly, her research at Imperial College has involved the development, optimisation and application of UPLC-MS methodologies for the analysis of biological samples, largely in the context of metabolic phenotyping: serum, urine, tissue, amniotic fluid, and microdialysates. Liz is applying these methods to biomedical research areas including toxicology, cardiovascular disease, neonatal disease and development, maternal exposures and effects on early childhood, and neurological diseases.